Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “hold” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued to investors on Friday. They presently have a $17.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 47.95% from the stock’s current price.

VRX has been the subject of a number of other research reports. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research report on Sunday, July 30th. Cantor Fitzgerald set a $23.00 target price on shares of Valeant Pharmaceuticals International and gave the company a “buy” rating in a research report on Tuesday. BidaskClub cut shares of Valeant Pharmaceuticals International from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Vetr raised shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “sell” rating and set a $13.68 target price for the company in a research report on Friday, October 6th. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $18.00 target price on shares of Valeant Pharmaceuticals International in a research report on Monday, October 9th. Five analysts have rated the stock with a sell rating, twelve have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average price target of $17.22.

Valeant Pharmaceuticals International (NYSE VRX) traded down $0.44 during trading hours on Friday, hitting $11.49. 16,166,812 shares of the company’s stock traded hands, compared to its average volume of 10,561,350. Valeant Pharmaceuticals International has a 12-month low of $8.31 and a 12-month high of $20.10. The firm has a market capitalization of $4,004.51, a P/E ratio of 1.73, a P/E/G ratio of 0.33 and a beta of -0.40. The company has a debt-to-equity ratio of 6.86, a quick ratio of 1.10 and a current ratio of 1.34.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. During the same period in the previous year, the company earned ($0.88) earnings per share. The company’s quarterly revenue was down 7.7% on a year-over-year basis. equities research analysts expect that Valeant Pharmaceuticals International will post 3.68 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/04/valeant-pharmaceuticals-internationals-vrx-hold-rating-reiterated-at-hc-wainwright.html.

In other news, Director Schutter Richard U. De acquired 10,000 shares of the stock in a transaction dated Monday, August 21st. The stock was bought at an average price of $14.33 per share, with a total value of $143,300.00. Following the completion of the purchase, the director now directly owns 77,479 shares of the company’s stock, valued at approximately $1,110,274.07. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 5.87% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Riggs Asset Managment Co. Inc. increased its stake in shares of Valeant Pharmaceuticals International by 118.2% in the third quarter. Riggs Asset Managment Co. Inc. now owns 8,330 shares of the specialty pharmaceutical company’s stock valued at $119,000 after buying an additional 4,512 shares during the period. NEXT Financial Group Inc increased its position in Valeant Pharmaceuticals International by 6.2% during the 2nd quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after purchasing an additional 600 shares during the period. Financial Architects Inc increased its position in Valeant Pharmaceuticals International by 10.5% during the 2nd quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,000 shares during the period. PNC Financial Services Group Inc. increased its position in Valeant Pharmaceuticals International by 33.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after purchasing an additional 2,763 shares during the period. Finally, Cetera Investment Advisers acquired a new stake in Valeant Pharmaceuticals International during the 2nd quarter valued at approximately $192,000. 50.21% of the stock is owned by institutional investors.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.